NCCS submitted comments to the Food and Drug Administration (FDA) as a follow-up to the Lung Cancer Patient-Focused Drug Development public meeting on June 28, 2013. The patient-focused drug development program is an initiative mandated by the Food and Drug Administration Safety and Innovation Act (FDASIA) and is intended to provide the ...

NCCS joined its patient advocate colleagues in the Cancer Leadership Council in comments on a Food and Drug Administration (FDA) document that provides guidance about the use of certain “expedited programs” that may be employed in the review of therapies for serious conditions.  The FDA has updated the guidance regarding ...

NCCS filed comments in support of proposed cancer care quality measures that will be utilized to assess the cancer care provided by the prospective payment system (PPS)-exempt cancer hospitals.  In its comments, NCCS focused on the outcome measure that will assess the performance of PPS-exempt institutions in preventing inpatient admission ...

NCCS is a member of the Alliance for Childhood Cancer and joined with the Alliance to support the introduction of the Carolyn Pryce Conquer Childhood Cancer Reauthorization Act. This legislation would make important progress to expand child, adolescent, and young adult cancer research, improve the tracking of cancer incidences, and ...

NCCS joined its colleagues in the Cancer Leadership Council in publishing a statement of principles to guide reform of Medicare payment for cancer care.  Major news outlets have suggested that Medicare beneficiaries are not receiving their cancer care due to the 2% cuts in Medicare payments required under the sequestration ...

NCCS joined colleagues in the cancer patient and provider community in providing advice to the Food and Drug Administration (FDA) regarding strategies to anticipate, mitigate, and report shortages of drugs and biologicals.  In the last several years, cancer patients and many others with serious and life-threatening illnesses have experienced disruptions ...

NCCS joined its colleagues in the patient advocate and cancer care provider community in offering comments to the Food and Drug Administration (FDA) on an alternative approval pathway for drugs to treat certain diseases where there is an unmet medical need.  FDA requested public comment on a proposal that was ...

NCCS joined colleagues in the cancer advocacy community in submitting comments regarding proposed standards for the expanded Medicaid program that was established by the Affordable Care Act.  The rules that have been proposed by the Centers for Medicare & Medicaid Services would grant a state great flexibility in the design ...

The Honorable Kathleen Sebelius Secretary Department of Health and Human Services 200 Independence Avenue, S.W. Washington, D.C. 20201 Re: CMS-9980-P, Patient Protection and Affordable Care Act; Standards Related to Essential Health Benefits, Actuarial Value, and Accreditation Dear Secretary Sebelius: The National Coalition for Cancer Survivorship (NCCS) appreciates the opportunity to ...

On December 26, 2012 the Cancer Leadership Council, a patient-centered forum of national advocacy organizations addressing public policy issues in cancer, filed comments on Essential Health Benefits. The National Coalition for Cancer Survivorship was one of 16 organizations representing cancer patients, physicians, researchers, and caregivers signing on to the comments. The comments ...